Australie - anglais - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - methylphenidate hydrochloride, quantity: 10 mg - tablet, uncoated - excipient ingredients: magnesium stearate; calcium phosphate; purified talc; lactose monohydrate; wheat starch; gelatin - treatment of attention-deficit hyperactivity disorder (adhd). treatment of narcolepsy.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; valsartan, quantity: 160 mg - tablet, film coated - excipient ingredients: crospovidone; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide red; macrogol 8000; magnesium stearate; hypromellose; colloidal anhydrous silica - co-diovan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; valsartan, quantity: 80 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; iron oxide yellow; colloidal anhydrous silica; crospovidone; purified talc; magnesium stearate; hypromellose; macrogol 8000; iron oxide red; titanium dioxide - co-diovan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - lumefantrine, quantity: 120 mg; artemether, quantity: 20 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; polysorbate 80; croscarmellose sodium; hypromellose - riamet tablet is indicated for the treatment of acute, uncomplicated malaria due to plasmodium falciparum in adults, children and infants of 5kg and above. riamet is indicated for the treatment of acute, uncomplicated malaria due to plasmodium falciparum in patients aged at least 12 years and weighing at least 35kg.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - carbamazepine, quantity: 100 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; carmellose sodium; magnesium stearate; colloidal anhydrous silica - epilepsy 1. complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalisation. 2. generalised tonic-clonic seizures 3. mixed seizure patterns incorporating the above. carbamazepine sandoz is suitable for monotherapy and combination therapy. carbamazepine sandoz is usually not effective in absence seizures, atonic seizures and myoclonic seizures and should not be used for status epilepticus (see precautions). trigeminal neuralgia for relief of pain in idiopathic trigeminal neuralgia and trigeminal neuralgia due to multiple sclerosis; and in idiopathic glossopharyngeal neuralgia. ( carbamazepine sandoz is not a simple analgesic and is not intended for trivial facial pain or headache). mania and bipolar affective disorders treatment of mania and maintenance treatment of bipolar affective disorders to prevent or attenuate recurrence.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - oxcarbazepine, quantity: 600 mg - tablet, film coated - excipient ingredients: hypromellose; macrogol 4000; iron oxide red; purified talc; titanium dioxide; microcrystalline cellulose; iron oxide black; magnesium stearate; colloidal anhydrous silica; crospovidone - trileptal is indicated for use as monotherapy or adjunctive therapy for the treatment of partial seizures and generalised tonic-clonic seizures, in adults and children.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - oxcarbazepine, quantity: 300 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; iron oxide yellow; purified talc; crospovidone; hypromellose; macrogol 8000; colloidal anhydrous silica; titanium dioxide; magnesium stearate - trileptal is indicated for use as monotherapy or adjunctive therapy for the treatment of partial seizures and generalised tonic-clonic seizures, in adults and children.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - candesartan cilexetil, quantity: 16 mg - tablet, uncoated - excipient ingredients: macrogol 8000; lactose monohydrate; iron oxide red; magnesium stearate; maize starch; carmellose sodium; hyprolose - treatment of hypertension. treatment of patients with heart failure and impaired left ventricular systolic function (left ventricular ejection fraction less than or equal to 40%) as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - candesartan cilexetil, quantity: 4 mg - tablet, uncoated - excipient ingredients: macrogol 8000; magnesium stearate; hyprolose; carmellose calcium; lactose monohydrate; maize starch - treatment of hypertension. treatment of patients with heart failure and impaired left ventricular systolic function (left ventricular ejection fraction less than or equal to 40%) as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: iron oxide yellow; lactose monohydrate; sodium starch glycollate; hypromellose; macrogol 8000; colloidal anhydrous silica; maize starch; magnesium stearate; microcrystalline cellulose; titanium dioxide; purified talc - for the treatment of postmenopausal women with hormone receptor positive breast cancer (see clinical trials). the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.